Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2016-10-10 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
独立董事候选人声明（陈永平）
Board/Management Information Classification · 95% confidence The document is a detailed declaration and statement by a candidate for an independent director position at Jiangsu Sihuan Bio Co., Ltd. It includes various compliance and qualification confirmations related to the candidate's independence, legal and regulatory adherence, and suitability for the role. There is no financial data, no mention of financial results, no report publication, or any other type of financial or regulatory filing. The content is focused on board/management information, specifically the nomination and qualifications of a board member candidate. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report but a declaration related to board membership.
2016-10-10 Chinese
关于2016年第一次临时股东大会增加临时提案暨召开2016年第一次临时股东大会补充通知的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2016 first extraordinary general meeting (临时股东大会) of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It includes information about additional proposals to be considered at the meeting, biographies of proposed board members, voting procedures (both in-person and online), and instructions for shareholders. The content focuses on board member changes, including proposals to dismiss and elect independent directors and board members. There are no financial statements, earnings data, or audit information. The document is not a report itself but an official notice and detailed information about the meeting and its agenda, including governance matters and voting instructions. This fits best under the category of Board/Management Information (MANG), as it announces changes in the company's board of directors and senior management positions and provides related procedural details for the shareholder meeting.
2016-10-10 Chinese
独立董事提名人声明（二）
Board/Management Information Classification · 95% confidence The document is a formal declaration related to the nomination of an independent director for Jiangsu Sihuan Bioengineering Co., Ltd. It contains detailed statements about the nominee's qualifications, compliance with legal and regulatory requirements, and independence criteria. There is no financial data, no mention of financial results, no reference to annual or interim reports, earnings releases, or other financial filings. The content focuses on board-related information, specifically the nomination of a board member. Therefore, this document fits best under the category of Board/Management Information (MANG). The document length is short (2681 characters), and it is not an announcement of a report but a substantive declaration about board nomination.
2016-10-10 Chinese
独立董事候选人声明（王福清）
Regulatory Filings Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Jiangsu SiHuan Bio Co., Ltd., outlining compliance with various regulatory and legal requirements for serving as an independent director. It includes statements about qualifications, conflicts of interest, regulatory compliance, and personal disclosures. There is no financial data, no report of financial results, no meeting materials, no voting results, and no announcement of a report publication. The document is a regulatory compliance statement related to corporate governance and director qualifications, which does not fit into categories like Annual Report, Interim Report, or Management Reports. It is not a certification letter per se but a formal declaration related to regulatory requirements. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory compliance documents that do not fit other categories.
2016-10-10 Chinese
简式权益变动报告书（已取消）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding by 中微小企业投资集团股份有限公司 in 江苏四环生物股份有限公司, including the number of shares held, percentage ownership, and the nature of the transaction (increase in holdings). The document references relevant Chinese securities laws and disclosure requirements, and it is clearly a formal report on a change in major shareholding. There is no indication that this is an announcement of a report publication or a certification. The content is substantive and specific to shareholding changes, fitting the definition of a Major Shareholding Notification (MRQ).
2016-10-09 Chinese
关于股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a short announcement regarding a change in shareholder equity, specifically an increase in shareholding by a shareholder without changing the largest shareholder. It includes details about share quantities and percentages before and after the transaction. There is no financial report, earnings data, or management discussion. The content fits the definition of a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds. The document length is short and focused solely on shareholding changes, confirming it is not a full report or announcement of a report publication.
2016-10-09 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.